Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Lung Disease Clear all
Active, not recruiting Phase 1 Interventional

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
Drug · Other
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed No phase listed Observational

Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

NCT05207293
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT07707895
View directory record Official record
Conditions
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Interventions
Obrixtamig, ZL-1310, Atezolizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed No phase listed Observational

Feasibility Study of Hematology Parameters in COVID-19 Disease

NCT04816630
View directory record Official record
Conditions
Covid19, Sepsis, Adults, Emergency Department
Interventions
CBC-Diff Monocyte Volume Width Distribution
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated Phase 1 Interventional

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions
PF-08046049
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

NCT07636785
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer, Colorectal Cancer (CRC)
Interventions
VMD-102
Drug
Lead sponsor
VM Discovery, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 26, 2026, 9:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed No phase listed Observational

Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo

NCT01033201
View directory record Official record
Conditions
Lung Transplant
Interventions
Confocal imaging
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 26, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
20
States / cities
Beverly Hills, California • Glendale, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Evaluation of the Impact of EHR-Alerts on Clinical Decision Support Pathway Use in Bronchiolitis, and the Impact of Pathway Use on the Prescription of High Flow Nasal Cannula and Other Elements of High Value Care.

NCT06932341
View directory record Official record
Conditions
Bronchiolitis
Interventions
Non-interruptive, Interruptive
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 24 Months
Enrollment
2,965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated Phase 4 Interventional Results available

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

NCT04381494
View directory record Official record
Conditions
Unresectable Stage III NSCLC
Interventions
Multiparametric Mobile Technology
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Results available

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

NCT03156114
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Ezabenlimab, BI 754111
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Reduce Pneumonia in Nursing Home Residents

NCT00975780
View directory record Official record
Conditions
Pneumonia, Lower Respiratory Tract Infection
Interventions
Enhanced Oral Care, Usual oral care
Other
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866
View directory record Official record
Conditions
Solid Tumors
Interventions
Bemarituzumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

NCT02594696
View directory record Official record
Conditions
Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, GI Cancer, Cancer
Interventions
Proactive Psychiatry Consultation (PPC)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 26, 2026, 9:33 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
79
States / cities
Tucson, Arizona • Corona, California • Duarte, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00387322
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
erlotinib hydrochloride, pemetrexed disodium
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2010 · Synced Sep 26, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 26, 2026, 9:33 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections

NCT01098227
View directory record Official record
Conditions
Bronchiolitis, Infection, Nitric Oxide
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 4 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Sep 26, 2026, 9:33 AM EDT
Not listed Not applicable Interventional

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

NCT00484640
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement, Pulmonary Embolism
Interventions
Coumadin
Drug
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
40 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2007 · Synced Sep 26, 2026, 9:33 AM EDT